Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors

C. Mah; K. O. Cresawn; T. J. Fraites; C. A. Pacak; M. A. Lewis; I. Zolotukhin; B. J. Byrne

doi:10.1038/sj.gt.3302550

Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors

C. Mah, K. O. Cresawn, T. J. Fraites, C. A. Pacak, M. A. Lewis, I. Zolotukhin, B. J. Byrne

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

Glycogen storage disease type II (GSDII) is caused by a lack of functional lysosomal acid α-glucosidase (GAA). Affected individuals store glycogen in lysosomes beginning during gestation, ultimately resulting in fatal hypertrophic cardiomyopathy and respiratory failure. We have assessed the utility of recombinant adeno-associated virus (rAAV) vectors to restore GAA activity in vivo in a mouse model of GSDII (Gaa^-/-). A single systemic administration of a rAAV serotype 1 (rAAV1) vector to neonate animals resulted in restored cardiac GAA activity to 6.4 times the normal level (mean =641±090% of normal (Gaa^+/+) levels with concomitant glycogen clearance) at 11 months postinjection. Greater than 20% of normal levels of GAA activity were also observed in the diaphragm and quadriceps muscles. Furthermore, functional correction of the soleus skeletal muscle was also observed compared to age-matched untreated Gaa^-/- control animals. These results demonstrate that rAAV1 vectors can mediate sustained therapeutic levels of correction of both skeletal and cardiac muscles in a model of fatal cardiomyopathy and muscular dystrophy.

Original language	English (US)
Pages (from-to)	1405-1409
Number of pages	5
Journal	Gene therapy
Volume	12
Issue number	18
DOIs	https://doi.org/10.1038/sj.gt.3302550
State	Published - Sep 2005
Externally published	Yes

Bibliographical note

Funding Information:
We gratefully acknowledge the University of Florida Powell Gene Therapy Center Vector Core Laboratory, which produced some of the rAAV vectors used in this study. This work was supported by grants from the National Institutes of Health (NHLBI P01 HL59412, NIDDK P01 DK58327), the Muscular Dystrophy Association, and the American Heart Association Florida and Puerto Rico Affiliate (KOC, TJF, CAP) and National Center (CM). BJB, The Johns Hopkins University, and the University of Florida could be entitled to patent royalties for inventions described in this manuscript.

Keywords

Acid alpha-glucosidase
Adeno-associated virus
Gene delivery
Glycogen storage disease type II
Pompe

Access

10.1038/sj.gt.3302550

OpenUrl availability

Full text

Cite this

@article{608f2b76e0b643a9baf8e52d05bdae75,

title = "Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors",

abstract = "Glycogen storage disease type II (GSDII) is caused by a lack of functional lysosomal acid α-glucosidase (GAA). Affected individuals store glycogen in lysosomes beginning during gestation, ultimately resulting in fatal hypertrophic cardiomyopathy and respiratory failure. We have assessed the utility of recombinant adeno-associated virus (rAAV) vectors to restore GAA activity in vivo in a mouse model of GSDII (Gaa-/-). A single systemic administration of a rAAV serotype 1 (rAAV1) vector to neonate animals resulted in restored cardiac GAA activity to 6.4 times the normal level (mean =641±090% of normal (Gaa+/+) levels with concomitant glycogen clearance) at 11 months postinjection. Greater than 20% of normal levels of GAA activity were also observed in the diaphragm and quadriceps muscles. Furthermore, functional correction of the soleus skeletal muscle was also observed compared to age-matched untreated Gaa-/- control animals. These results demonstrate that rAAV1 vectors can mediate sustained therapeutic levels of correction of both skeletal and cardiac muscles in a model of fatal cardiomyopathy and muscular dystrophy.",

keywords = "Acid alpha-glucosidase, Adeno-associated virus, Gene delivery, Glycogen storage disease type II, Pompe",

author = "C. Mah and Cresawn, {K. O.} and Fraites, {T. J.} and Pacak, {C. A.} and Lewis, {M. A.} and I. Zolotukhin and Byrne, {B. J.}",

note = "Funding Information: We gratefully acknowledge the University of Florida Powell Gene Therapy Center Vector Core Laboratory, which produced some of the rAAV vectors used in this study. This work was supported by grants from the National Institutes of Health (NHLBI P01 HL59412, NIDDK P01 DK58327), the Muscular Dystrophy Association, and the American Heart Association Florida and Puerto Rico Affiliate (KOC, TJF, CAP) and National Center (CM). BJB, The Johns Hopkins University, and the University of Florida could be entitled to patent royalties for inventions described in this manuscript.",

year = "2005",

month = sep,

doi = "10.1038/sj.gt.3302550",

language = "English (US)",

volume = "12",

pages = "1405--1409",

journal = "Gene therapy",

issn = "0969-7128",

publisher = "Nature Publishing Group",

number = "18",

}

TY - JOUR

T1 - Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors

AU - Mah, C.

AU - Cresawn, K. O.

AU - Fraites, T. J.

AU - Pacak, C. A.

AU - Lewis, M. A.

AU - Zolotukhin, I.

AU - Byrne, B. J.

N1 - Funding Information: We gratefully acknowledge the University of Florida Powell Gene Therapy Center Vector Core Laboratory, which produced some of the rAAV vectors used in this study. This work was supported by grants from the National Institutes of Health (NHLBI P01 HL59412, NIDDK P01 DK58327), the Muscular Dystrophy Association, and the American Heart Association Florida and Puerto Rico Affiliate (KOC, TJF, CAP) and National Center (CM). BJB, The Johns Hopkins University, and the University of Florida could be entitled to patent royalties for inventions described in this manuscript.

PY - 2005/9

Y1 - 2005/9

N2 - Glycogen storage disease type II (GSDII) is caused by a lack of functional lysosomal acid α-glucosidase (GAA). Affected individuals store glycogen in lysosomes beginning during gestation, ultimately resulting in fatal hypertrophic cardiomyopathy and respiratory failure. We have assessed the utility of recombinant adeno-associated virus (rAAV) vectors to restore GAA activity in vivo in a mouse model of GSDII (Gaa-/-). A single systemic administration of a rAAV serotype 1 (rAAV1) vector to neonate animals resulted in restored cardiac GAA activity to 6.4 times the normal level (mean =641±090% of normal (Gaa+/+) levels with concomitant glycogen clearance) at 11 months postinjection. Greater than 20% of normal levels of GAA activity were also observed in the diaphragm and quadriceps muscles. Furthermore, functional correction of the soleus skeletal muscle was also observed compared to age-matched untreated Gaa-/- control animals. These results demonstrate that rAAV1 vectors can mediate sustained therapeutic levels of correction of both skeletal and cardiac muscles in a model of fatal cardiomyopathy and muscular dystrophy.

AB - Glycogen storage disease type II (GSDII) is caused by a lack of functional lysosomal acid α-glucosidase (GAA). Affected individuals store glycogen in lysosomes beginning during gestation, ultimately resulting in fatal hypertrophic cardiomyopathy and respiratory failure. We have assessed the utility of recombinant adeno-associated virus (rAAV) vectors to restore GAA activity in vivo in a mouse model of GSDII (Gaa-/-). A single systemic administration of a rAAV serotype 1 (rAAV1) vector to neonate animals resulted in restored cardiac GAA activity to 6.4 times the normal level (mean =641±090% of normal (Gaa+/+) levels with concomitant glycogen clearance) at 11 months postinjection. Greater than 20% of normal levels of GAA activity were also observed in the diaphragm and quadriceps muscles. Furthermore, functional correction of the soleus skeletal muscle was also observed compared to age-matched untreated Gaa-/- control animals. These results demonstrate that rAAV1 vectors can mediate sustained therapeutic levels of correction of both skeletal and cardiac muscles in a model of fatal cardiomyopathy and muscular dystrophy.

KW - Acid alpha-glucosidase

KW - Adeno-associated virus

KW - Gene delivery

KW - Glycogen storage disease type II

KW - Pompe

UR - http://www.scopus.com/inward/record.url?scp=30744470902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30744470902&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302550

DO - 10.1038/sj.gt.3302550

M3 - Article

C2 - 15920463

AN - SCOPUS:30744470902

SN - 0969-7128

VL - 12

SP - 1405

EP - 1409

JO - Gene therapy

JF - Gene therapy

IS - 18

ER -

Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this